Lung Cancer Trials Ask AI to find trials
TerminatedPhase 1 / Phase 2NCT00807612

QUILT-2.017: Phase 1b/2 Study of AMG 479 in Combination With Paclitaxel and Carboplatin for 1st Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer

This is a global, multicenter, 2-part, open-label phase 1b and single-arm phase 2 study designed to evaluate the safety and efficacy of AMG 479 in combination with paclitaxel and carboplatin for the first-line treatment of advanced squamous non-small cell lung carcinoma.

Checked against the public recordLast updated Sep 25, 2024 · Source: ClinicalTrials.gov

StatusTerminated
PhasePhase 1 / Phase 2
U.S. locations25
SponsorNantCell, Inc.
01
Study overview

What this study is about

Purpose
Treatment
Study type
Interventional
Phase
Phase 1 / Phase 2
Sponsor
NantCell, Inc.
Interventions being studied
Biological: AMG 479; Biological: AMG 479; Drug: Carboplatin; Biological: AMG 479; Drug: Paclitaxel
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type
Non-small cell lung cancer (NSCLC)→
Treatment approach
Chemotherapy→
03
Public criteria

Who may be able to participate

Inclusion Criteria: * Histologically or cytologically confirmed advanced squamous NSCLC * Measurable disease as defined per modified RECIST criteria * ECOG performance status of 0 or 1 * ≥18 years old * Adequate glycemic function, for subjects with known diabetes Exclusion Criteria: * Untreated or symptomatic central nervous system (CNS) metastases * Prior anti-cancer therapy as follows: Any prior chemotherapy for squamous NSCLC; Any prior adjuvant or neoadjuvant chemotherapy for squamous NSCLC; Any prior chemoradiation for squamous NSCLC; Central (chest) radiation therapy ≤ 28 days prior to enrollment, radiation therapy for peripheral lesions≤14 days prior to enrollment for squamous NSCLC

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Research SiteFayetteville, Arkansas
  • Research SiteFayetteville, Arkansas
  • Research SiteFort Wayne, Indiana
  • Research SiteFort Wayne, Indiana
  • Research SiteIndianapolis, Indiana
  • Research SiteIndianapolis, Indiana
  • Research SiteIndianapolis, Indiana
  • Research SiteLafayette, Indiana
  • Research SiteLafayette, Indiana
  • Research SiteNew Albany, Indiana
  • Research SiteNew Albany, Indiana
  • Research SitePaducah, Kentucky

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Sep 25, 2024. Always confirm current availability with the study team.

View original record ↗